drugset / Trial / NCT00623545

Bioenergetic Alterations After Exenatide Administration

NCT00623545

Phase 4 Completed 28 enrolled University of Wisconsin, Madison
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to find out how exenatide causes weight loss. Specifically, the study is assessing how exenatide may change how people take in energy (energy intake), as well as how it may effect how people use energy (energy expenditure).

Timeline

Start
2008-01
Primary completion
2010-04
Completion
2010-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Exenatide Peptide 10 ug Subcutaneous

Indications

No indication recorded.